ANATARA LIFESCIENCES LTD - Announcements

0.00%

0.8¢

Market Cap $1.708M

Healthcare Biotechnology

Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is... Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is engaged in developing evidence-based solutions for gastrointestinal diseases in humans and animals. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

ANR	Appendix 4E & Financial Report 30 June 2025	PRICE SENSITIVE	13/08/25	1.04MB	Share
ANR	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/25	649.95KB	Share
ANR	Anatara receives $969,455 in R&D Tax Incentive for FY25	PRICE SENSITIVE	28/07/25	166.75KB	Share
ANR	Company Update	PRICE SENSITIVE	09/07/25	290.95KB	Share
ANR	Hong Kong Patent Granted for GaRP	PRICE SENSITIVE	19/05/25	232.29KB	Share
ANR	Phase II GaRP-IBS Trial Internal Analyses of Data Subsets	PRICE SENSITIVE	16/05/25	1.01MB	Share
ANR	Funding Advance on R&D Refund	PRICE SENSITIVE	01/05/25	228.33KB	Share
ANR	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	479.16KB	Share
ANR	Phase II GaRP-IBS Trial Headline Analysis of Results	PRICE SENSITIVE	17/04/25	370.8KB	Share
ANR	Phase II GaRP-IBS Trial & Anti-Obesity Project Updates	PRICE SENSITIVE	10/03/25	291.45KB	Share
ANR	Trading Halt	PRICE SENSITIVE	06/03/25	257.29KB	Share
ANR	Appendix 4D & Half Year Report 31 December 2024	PRICE SENSITIVE	25/02/25	548.16KB	Share
ANR	Phase II GaRP-IBS Trial & Anti-Obesity Project Updates	PRICE SENSITIVE	20/02/25	289.42KB	Share
ANR	Australian Patent Granted for GaRP Product	PRICE SENSITIVE	28/01/25	284.34KB	Share
ANR	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	15/01/25	522.33KB	Share
ANR	GaRP-IBS Clinical Trial Update	PRICE SENSITIVE	13/12/24	283.75KB	Share
ANR	GaRP-IBS Clinical Trial Update	PRICE SENSITIVE	04/12/24	305.99KB	Share
ANR	Share Purchase Plan Offer Booklet	PRICE SENSITIVE	27/11/24	373.89KB	Share
ANR	Successful Placement of $660k and Share Purchase Plan	PRICE SENSITIVE	15/11/24	173.7KB	Share
ANR	Chair's Address to Shareholders	PRICE SENSITIVE	14/11/24	176.07KB	Share
ANR	Trading Halt	PRICE SENSITIVE	13/11/24	547.71KB	Share
ANR	Pause in Trading	PRICE SENSITIVE	13/11/24	116.12KB	Share
ANR	Appendix 4C & Q1 FY25 Activities Report	PRICE SENSITIVE	31/10/24	520.43KB	Share
ANR	GaRP-IBS Irritable Bowel Syndrome Clinical Trial Update	PRICE SENSITIVE	08/10/24	315.22KB	Share
ANR	Anatara's GaRP granted EU patent	PRICE SENSITIVE	20/09/24	233.81KB	Share
ANR	GaRP Irritable Bowel Syndrome Clinical Trial Update	PRICE SENSITIVE	30/08/24	305.09KB	Share
ANR	$626,000 received in R&D Tax Incentive for FY24	PRICE SENSITIVE	29/08/24	168.61KB	Share
ANR	Appendix 4E & Financial Report 30 June 2024	PRICE SENSITIVE	22/08/24	808.14KB	Share
ANR	Appendix 4C & Q4 FY24 Activities Report	PRICE SENSITIVE	30/07/24	564.9KB	Share
ANR	Anatara successful placement for $1.0M	PRICE SENSITIVE	01/05/24	284.62KB	Share
ANR	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	461.51KB	Share
ANR	Trading Halt	PRICE SENSITIVE	29/04/24	215.62KB	Share
ANR	Recruitment for Pivotal Phase II IBS Clinical Trial Stage 2	PRICE SENSITIVE	29/02/24	286.25KB	Share
ANR	Appendix 4D & Half Year Report 31 December 2023	PRICE SENSITIVE	28/02/24	473.92KB	Share
ANR	Appendix 4C & Q2 FY24 Activities Report	PRICE SENSITIVE	24/01/24	652.83KB	Share
ANR	Entitlement Offer Results	PRICE SENSITIVE	07/12/23	199.22KB	Share
ANR	Non-Renounceable Entitlement Offer Booklet	PRICE SENSITIVE	13/11/23	607.32KB	Share
ANR	Entitlement offer opens and dispatch of Offer Booklet	PRICE SENSITIVE	13/11/23	189.37KB	Share
ANR	GaRP Clinical Trial AGM Presentation	PRICE SENSITIVE	10/11/23	1.12MB	Share
ANR	AGM Chair Address	PRICE SENSITIVE	10/11/23	161.46KB	Share
ANR	Cleansing Notice	PRICE SENSITIVE	03/11/23	177.93KB	Share
ANR	Anatara launches a partially underwritten Entitlement Offer	PRICE SENSITIVE	03/11/23	275.53KB	Share
ANR	Trading Halt	PRICE SENSITIVE	01/11/23	217.82KB	Share
ANR	Appendix 4C & Q1 FY24 Activities Report	PRICE SENSITIVE	31/10/23	621.82KB	Share
ANR	Webinar Investor Presentation	PRICE SENSITIVE	19/10/23	4.5MB	Share
ANR	Anatara IBS trial positive secondary endpoint data analysis	PRICE SENSITIVE	17/10/23	451.5KB	Share
ANR	Trading Halt	PRICE SENSITIVE	16/10/23	530.43KB	Share
ANR	ANR announces Positive Results from Stage 1 of IBS trial	PRICE SENSITIVE	28/09/23	373.51KB	Share
ANR	Trading Halt	PRICE SENSITIVE	26/09/23	527.46KB	Share
ANR	Pause in Trading	PRICE SENSITIVE	26/09/23	116.24KB	Share
ANR	IBS clinical trial Stage 1 patients finalised	PRICE SENSITIVE	31/08/23	336.59KB	Share
ANR	Appendix 4E & Audited Financial Statements 30 June 2023	PRICE SENSITIVE	24/08/23	761.64KB	Share
ANR	$923,235 in R&D tax incentive received	PRICE SENSITIVE	14/08/23	180.46KB	Share
ANR	Appendix 4C & Q4 FY23 Activities Report	PRICE SENSITIVE	31/07/23	497.72KB	Share
ANR	Anatara Update on GaRP Irritable Bowel Syndrome Trial	PRICE SENSITIVE	06/06/23	327.06KB	Share
ANR	Appendix 4C & Q3 FY23 Activities Report	PRICE SENSITIVE	20/04/23	492.13KB	Share
ANR	Anatara Company Update	PRICE SENSITIVE	10/03/23	281.34KB	Share
ANR	Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/23	348.26KB	Share
ANR	Placement of Shortfall from Entitlement Offer	PRICE SENSITIVE	21/02/23	170.37KB	Share
ANR	Revised Appendix 4C	PRICE SENSITIVE	13/01/23	380.13KB	Share
ANR	Appendix 4C & Q2 FY23 Activities Report	PRICE SENSITIVE	12/01/23	490.8KB	Share
ANR	Completion of Non-renounceable Entitlement Offer and Shortfa	PRICE SENSITIVE	25/11/22	141.11KB	Share
ANR	Appendix 4C & Q1 FY23 Activities Report	PRICE SENSITIVE	28/10/22	517.85KB	Share
ANR	Entitlement Offer Prospectus	PRICE SENSITIVE	21/10/22	521.13KB	Share
ANR	Placement and Entitlement Offer	PRICE SENSITIVE	21/10/22	260.74KB	Share
ANR	Trading Halt	PRICE SENSITIVE	19/10/22	596.01KB	Share
ANR	Anatara Investor Presentation	PRICE SENSITIVE	13/10/22	2.15MB	Share
ANR	3FDC Clinical Trial update	PRICE SENSITIVE	03/10/22	204.51KB	Share
ANR	Appendix 4E & Audited Financial Report 30 June 2022	PRICE SENSITIVE	29/08/22	596.87KB	Share
ANR	Operational Update	PRICE SENSITIVE	11/08/22	411.98KB	Share
ANR	Q4 FY22 Activities Report	PRICE SENSITIVE	01/08/22	379.53KB	Share
ANR	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	184.85KB	Share
ANR	Clinical Trial and Operational Update	PRICE SENSITIVE	20/05/22	237.02KB	Share
ANR	Anatara Lifesciences announces leadership change	PRICE SENSITIVE	05/05/22	231.72KB	Share
ANR	Appendix 4C and Q3 FY22 Activities Report	PRICE SENSITIVE	29/04/22	455.76KB	Share
ANR	Clinical Trials Update	PRICE SENSITIVE	31/03/22	217.17KB	Share
ANR	Half Year Accounts	PRICE SENSITIVE	24/02/22	423.02KB	Share
ANR	Clinical Trials Update	PRICE SENSITIVE	17/02/22	206.65KB	Share
ANR	Appendix 4C and Q2 FY22 Activities Report	PRICE SENSITIVE	28/01/22	478.5KB	Share
ANR	Appendix 4C and Q2 FY22 Activities Report	PRICE SENSITIVE	27/01/22	371.97KB	Share
ANR	Clinical Trials Update	PRICE SENSITIVE	16/12/21	172.33KB	Share
ANR	AGM CEO Presentation	PRICE SENSITIVE	16/11/21	1.05MB	Share
ANR	Chairman's Address to Shareholders	PRICE SENSITIVE	16/11/21	244.05KB	Share
ANR	Appendix 4C & Q1 FY22 Activities Report	PRICE SENSITIVE	29/10/21	350.69KB	Share
ANR	Investor Presentation	PRICE SENSITIVE	06/09/21	1.78MB	Share
ANR	Appendix 4E & Financial Report 30 June 2021	PRICE SENSITIVE	24/08/21	977.89KB	Share
ANR	Successful Piglet Study	PRICE SENSITIVE	06/08/21	204.94KB	Share
ANR	Monthly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/21	399.65KB	Share
ANR	Appendix 4C - quarterly	PRICE SENSITIVE	27/04/21	499.7KB	Share
ANR	Anatara announces Australian patent grant for Detach	PRICE SENSITIVE	16/04/21	257.69KB	Share
ANR	Market Update	PRICE SENSITIVE	07/04/21	257.25KB	Share
ANR	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/21	620.85KB	Share
ANR	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/21	381.22KB	Share
ANR	$1.4m raised through the completed SPP	PRICE SENSITIVE	16/11/20	165.21KB	Share
ANR	SPP Offer Booklet	PRICE SENSITIVE	28/10/20	385.11KB	Share
ANR	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/20	418.66KB	Share
ANR	Completed Placement and announced Share Purchase Plan	PRICE SENSITIVE	21/10/20	255.66KB	Share
ANR	Trading Halt	PRICE SENSITIVE	19/10/20	141.23KB	Share
ANR	Appendix 4E & Financial Report 30 June 2020	PRICE SENSITIVE	24/08/20	1.18MB	Share
ANR	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/20	566.49KB	Share

ANR Appendix 4E & Financial Report 30 June 2025
13/08/25	PRICE SENSITIVE	1.04MB	Share
ANR Quarterly Activities/Appendix 4C Cash Flow Report
29/07/25	PRICE SENSITIVE	649.95KB	Share
ANR Anatara receives $969,455 in R&D Tax Incentive for FY25
28/07/25	PRICE SENSITIVE	166.75KB	Share
ANR Company Update
09/07/25	PRICE SENSITIVE	290.95KB	Share
ANR Hong Kong Patent Granted for GaRP
19/05/25	PRICE SENSITIVE	232.29KB	Share
ANR Phase II GaRP-IBS Trial Internal Analyses of Data Subsets
16/05/25	PRICE SENSITIVE	1.01MB	Share
ANR Funding Advance on R&D Refund
01/05/25	PRICE SENSITIVE	228.33KB	Share
ANR Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	479.16KB	Share
ANR Phase II GaRP-IBS Trial Headline Analysis of Results
17/04/25	PRICE SENSITIVE	370.8KB	Share
ANR Phase II GaRP-IBS Trial & Anti-Obesity Project Updates
10/03/25	PRICE SENSITIVE	291.45KB	Share
ANR Trading Halt
06/03/25	PRICE SENSITIVE	257.29KB	Share
ANR Appendix 4D & Half Year Report 31 December 2024
25/02/25	PRICE SENSITIVE	548.16KB	Share
ANR Phase II GaRP-IBS Trial & Anti-Obesity Project Updates
20/02/25	PRICE SENSITIVE	289.42KB	Share
ANR Australian Patent Granted for GaRP Product
28/01/25	PRICE SENSITIVE	284.34KB	Share
ANR Quarterly Activities/Appendix 4C Cash Flow Report
15/01/25	PRICE SENSITIVE	522.33KB	Share
ANR GaRP-IBS Clinical Trial Update
13/12/24	PRICE SENSITIVE	283.75KB	Share
ANR GaRP-IBS Clinical Trial Update
04/12/24	PRICE SENSITIVE	305.99KB	Share
ANR Share Purchase Plan Offer Booklet
27/11/24	PRICE SENSITIVE	373.89KB	Share
ANR Successful Placement of $660k and Share Purchase Plan
15/11/24	PRICE SENSITIVE	173.7KB	Share
ANR Chair's Address to Shareholders
14/11/24	PRICE SENSITIVE	176.07KB	Share
ANR Trading Halt
13/11/24	PRICE SENSITIVE	547.71KB	Share
ANR Pause in Trading
13/11/24	PRICE SENSITIVE	116.12KB	Share
ANR Appendix 4C & Q1 FY25 Activities Report
31/10/24	PRICE SENSITIVE	520.43KB	Share
ANR GaRP-IBS Irritable Bowel Syndrome Clinical Trial Update
08/10/24	PRICE SENSITIVE	315.22KB	Share
ANR Anatara's GaRP granted EU patent
20/09/24	PRICE SENSITIVE	233.81KB	Share
ANR GaRP Irritable Bowel Syndrome Clinical Trial Update
30/08/24	PRICE SENSITIVE	305.09KB	Share
ANR $626,000 received in R&D Tax Incentive for FY24
29/08/24	PRICE SENSITIVE	168.61KB	Share
ANR Appendix 4E & Financial Report 30 June 2024
22/08/24	PRICE SENSITIVE	808.14KB	Share
ANR Appendix 4C & Q4 FY24 Activities Report
30/07/24	PRICE SENSITIVE	564.9KB	Share
ANR Anatara successful placement for $1.0M
01/05/24	PRICE SENSITIVE	284.62KB	Share
ANR Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	461.51KB	Share
ANR Trading Halt
29/04/24	PRICE SENSITIVE	215.62KB	Share
ANR Recruitment for Pivotal Phase II IBS Clinical Trial Stage 2
29/02/24	PRICE SENSITIVE	286.25KB	Share
ANR Appendix 4D & Half Year Report 31 December 2023
28/02/24	PRICE SENSITIVE	473.92KB	Share
ANR Appendix 4C & Q2 FY24 Activities Report
24/01/24	PRICE SENSITIVE	652.83KB	Share
ANR Entitlement Offer Results
07/12/23	PRICE SENSITIVE	199.22KB	Share
ANR Non-Renounceable Entitlement Offer Booklet
13/11/23	PRICE SENSITIVE	607.32KB	Share
ANR Entitlement offer opens and dispatch of Offer Booklet
13/11/23	PRICE SENSITIVE	189.37KB	Share
ANR GaRP Clinical Trial AGM Presentation
10/11/23	PRICE SENSITIVE	1.12MB	Share
ANR AGM Chair Address
10/11/23	PRICE SENSITIVE	161.46KB	Share
ANR Cleansing Notice
03/11/23	PRICE SENSITIVE	177.93KB	Share
ANR Anatara launches a partially underwritten Entitlement Offer
03/11/23	PRICE SENSITIVE	275.53KB	Share
ANR Trading Halt
01/11/23	PRICE SENSITIVE	217.82KB	Share
ANR Appendix 4C & Q1 FY24 Activities Report
31/10/23	PRICE SENSITIVE	621.82KB	Share
ANR Webinar Investor Presentation
19/10/23	PRICE SENSITIVE	4.5MB	Share
ANR Anatara IBS trial positive secondary endpoint data analysis
17/10/23	PRICE SENSITIVE	451.5KB	Share
ANR Trading Halt
16/10/23	PRICE SENSITIVE	530.43KB	Share
ANR ANR announces Positive Results from Stage 1 of IBS trial
28/09/23	PRICE SENSITIVE	373.51KB	Share
ANR Trading Halt
26/09/23	PRICE SENSITIVE	527.46KB	Share
ANR Pause in Trading
26/09/23	PRICE SENSITIVE	116.24KB	Share
ANR IBS clinical trial Stage 1 patients finalised
31/08/23	PRICE SENSITIVE	336.59KB	Share
ANR Appendix 4E & Audited Financial Statements 30 June 2023
24/08/23	PRICE SENSITIVE	761.64KB	Share
ANR $923,235 in R&D tax incentive received
14/08/23	PRICE SENSITIVE	180.46KB	Share
ANR Appendix 4C & Q4 FY23 Activities Report
31/07/23	PRICE SENSITIVE	497.72KB	Share
ANR Anatara Update on GaRP Irritable Bowel Syndrome Trial
06/06/23	PRICE SENSITIVE	327.06KB	Share
ANR Appendix 4C & Q3 FY23 Activities Report
20/04/23	PRICE SENSITIVE	492.13KB	Share
ANR Anatara Company Update
10/03/23	PRICE SENSITIVE	281.34KB	Share
ANR Half Yearly Report and Accounts
24/02/23	PRICE SENSITIVE	348.26KB	Share
ANR Placement of Shortfall from Entitlement Offer
21/02/23	PRICE SENSITIVE	170.37KB	Share
ANR Revised Appendix 4C
13/01/23	PRICE SENSITIVE	380.13KB	Share
ANR Appendix 4C & Q2 FY23 Activities Report
12/01/23	PRICE SENSITIVE	490.8KB	Share
ANR Completion of Non-renounceable Entitlement Offer and Shortfa
25/11/22	PRICE SENSITIVE	141.11KB	Share
ANR Appendix 4C & Q1 FY23 Activities Report
28/10/22	PRICE SENSITIVE	517.85KB	Share
ANR Entitlement Offer Prospectus
21/10/22	PRICE SENSITIVE	521.13KB	Share
ANR Placement and Entitlement Offer
21/10/22	PRICE SENSITIVE	260.74KB	Share
ANR Trading Halt
19/10/22	PRICE SENSITIVE	596.01KB	Share
ANR Anatara Investor Presentation
13/10/22	PRICE SENSITIVE	2.15MB	Share
ANR 3FDC Clinical Trial update
03/10/22	PRICE SENSITIVE	204.51KB	Share
ANR Appendix 4E & Audited Financial Report 30 June 2022
29/08/22	PRICE SENSITIVE	596.87KB	Share
ANR Operational Update
11/08/22	PRICE SENSITIVE	411.98KB	Share
ANR Q4 FY22 Activities Report
01/08/22	PRICE SENSITIVE	379.53KB	Share
ANR Quarterly Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	184.85KB	Share
ANR Clinical Trial and Operational Update
20/05/22	PRICE SENSITIVE	237.02KB	Share
ANR Anatara Lifesciences announces leadership change
05/05/22	PRICE SENSITIVE	231.72KB	Share
ANR Appendix 4C and Q3 FY22 Activities Report
29/04/22	PRICE SENSITIVE	455.76KB	Share
ANR Clinical Trials Update
31/03/22	PRICE SENSITIVE	217.17KB	Share
ANR Half Year Accounts
24/02/22	PRICE SENSITIVE	423.02KB	Share
ANR Clinical Trials Update
17/02/22	PRICE SENSITIVE	206.65KB	Share
ANR Appendix 4C and Q2 FY22 Activities Report
28/01/22	PRICE SENSITIVE	478.5KB	Share
ANR Appendix 4C and Q2 FY22 Activities Report
27/01/22	PRICE SENSITIVE	371.97KB	Share
ANR Clinical Trials Update
16/12/21	PRICE SENSITIVE	172.33KB	Share
ANR AGM CEO Presentation
16/11/21	PRICE SENSITIVE	1.05MB	Share
ANR Chairman's Address to Shareholders
16/11/21	PRICE SENSITIVE	244.05KB	Share
ANR Appendix 4C & Q1 FY22 Activities Report
29/10/21	PRICE SENSITIVE	350.69KB	Share
ANR Investor Presentation
06/09/21	PRICE SENSITIVE	1.78MB	Share
ANR Appendix 4E & Financial Report 30 June 2021
24/08/21	PRICE SENSITIVE	977.89KB	Share
ANR Successful Piglet Study
06/08/21	PRICE SENSITIVE	204.94KB	Share
ANR Monthly Activities/Appendix 4C Cash Flow Report
28/07/21	PRICE SENSITIVE	399.65KB	Share
ANR Appendix 4C - quarterly
27/04/21	PRICE SENSITIVE	499.7KB	Share
ANR Anatara announces Australian patent grant for Detach
16/04/21	PRICE SENSITIVE	257.69KB	Share
ANR Market Update
07/04/21	PRICE SENSITIVE	257.25KB	Share
ANR Half Yearly Report and Accounts
23/02/21	PRICE SENSITIVE	620.85KB	Share
ANR Appendix 4C - quarterly
28/01/21	PRICE SENSITIVE	381.22KB	Share
ANR $1.4m raised through the completed SPP
16/11/20	PRICE SENSITIVE	165.21KB	Share
ANR SPP Offer Booklet
28/10/20	PRICE SENSITIVE	385.11KB	Share
ANR Appendix 4C - quarterly
28/10/20	PRICE SENSITIVE	418.66KB	Share
ANR Completed Placement and announced Share Purchase Plan
21/10/20	PRICE SENSITIVE	255.66KB	Share
ANR Trading Halt
19/10/20	PRICE SENSITIVE	141.23KB	Share
ANR Appendix 4E & Financial Report 30 June 2020
24/08/20	PRICE SENSITIVE	1.18MB	Share
ANR Appendix 4C - quarterly
29/07/20	PRICE SENSITIVE	566.49KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.8¢		Change 0.000(0.00%)		Mkt cap ! $1.708M

Open	High	Low	Value	Volume
0.8¢	0.8¢	0.8¢	$1.84K	230.0K

Buyers (Bids)

No.	Vol.	Price($)
1	8893	0.8¢

Sellers (Offers)

Price($)	Vol.	No.
0.9¢	908675	3

View Market Depth

No.	Vol.	Price($)
1	8893	0.008
6	1101919	0.007
9	2276169	0.006
10	3812000	0.005
6	3500052	0.004

Price($)	Vol.	No.
0.009	908675	3
0.010	1502600	4
0.011	520150	2
0.012	755000	2
0.013	300000	1

Last trade - 15.55pm 04/09/2025 (20 minute delay)

ANR (ASX) Chart

ANATARA LIFESCIENCES LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories